The Changing Role Of Equity Research Actually, the

New Post Public Reply Private Reply Replies (0) Message Board
NITE

The Changing Role Of Equity Research
Actually, the title of this article is a bit misleading, because the role of research hasn't changed since the first trade occurred under the buttonwood tree on Manhattan Island. What has changed is the environments (bull and bear markets) that influence research.



Research and the Stock Market
The role of research is to provide information to the market. A lack of information creates inefficiencies that result in stocks being misrepresented (over- or under-valued). Analysts use their expertise and spend a lot of time analyzing a stock, its industry and its peer group to provide earnings and valuation estimates. Research is valuable because it fills information gaps so that each individual investor does not need to analyze every stock. This division of labor makes the market more efficient.

Research in Bull and Bear Markets
If the role of research has always been so "noble," why is it in such a state of ill-repute? There are two reasons: firstly, the current bear market gives us a new perspective to evaluate the excesses of the last bull market; secondly, investors need to blame somebody.

In every bull market, there are excesses that become apparent only in the bear market that follows. Whether it is tulips or transistors, each age has its mania that distorts the normal functioning of the market. In the rush to make money, rationality is the first casualty. Investors rush to jump on the bandwagon and the market over-allocates capital to the "hot" sector(s). This herd mentality is the reason why bull markets have funded so many "me-too" ideas throughout history.

Research is a function of the market and is influenced by these swings. In a bull market, investment bankers, the media and investors pressure analysts to focus on the hot sectors. Some analysts morph into promoters as they ride the market. Those analysts that remain rational practitioners are ignored and their research reports go unread. During the late 1990s, the business media catered to the audience's demands and gave the spotlight to the famous talking heads that are now under investigation.

Seeking to blame someone for investment losses is a normal event in bear markets. It happened in the 1930s and the 1970s, and it's occurring today. Some of the criticisms are deserved, but the need to provide information has not changed.

Research in Today's Market
To discuss the role of research in today's market, we need to differentiate between Wall Street research and other research. Wall Street research is provided by the major brokerage firms, both on and off Wall Street. Other research is produced by independent research firms and small boutique brokerage firms.

This differentiation is important. First, Wall Street research has become focused on big cap, very liquid stocks and ignores the majority (over 60% based on research) of publicly-traded stocks. This myopic focus on a small number of stocks is the result of deregulation and industry consolidation. In order to remain profitable, Wall Street firms have focused on big-cap stocks to generate highly lucrative investment banking deals and trade profits.

Those companies that are likely to provide the research firms with sizable investment banking deals are the stocks that are determined worthy of being followed by the market. The stock's long-term investment potential is secondary. The second reason to distinguish Wall Street from other research is that most of the blame for the excesses of the last bull market is rightfully placed on Wall Street.

Other research is filling the information gap created by Wall Street. Independent research firms and boutique brokerage firms are providing research on the stocks that have been orphaned by Wall Street. Investors, now educated in the benefits of electronic trading, may not be willing to support boutique brokerage firms for their research by opening an account and paying higher commissions.

This means that independent research firms are becoming the main source of information on the majority of stocks, but investors are reluctant to pay for research, because they don't really know what they are paying for until well after the purchase. Unfortunately, not all research is worth buying. I have purchased reports from reputable sources only to find them inaccurate and misleading. (For more reasons to do your research read: What Is The Impact Of Research On Stock Prices?)

Who Pays for Research? Big Investors Do!
The ironic thing is that while research has proven to be valuable, individual investors do not seem to want to pay for it. This may be because, under the traditional system, brokerage houses provided research in order to gain and keep clients. Investors just had to ask their brokers for a report and retained it at no charge. What seems to have gone unrealized is that the commissions pay for that research.

A good indicator of the value of research is the amount institutional investors are willing to pay for it. Institutional investors hire their own analysts to gain a competitive edge over other investors. They also pay (often handsomely) independent research firms for additional research. Institutions also pay for the sell-side research they receive (either with dollars or by giving the supplying brokerage firm trades to execute). All this amounts to big money, but the institutions realize that research is integral to making successful investment decisions. (For more read The Impact of Sell-Side Research.)
If investors are unwilling to buy research how will the market correct the imbalance caused by the lack of coverage? The solution may be found by looking at the issue a slightly different way.

The Growing Role of Fee-Based Research
Fee-based research increases market efficiency and bridges the gap between investors who want research (without paying) and companies who realize that Wall Street is not likely to provide research on their stock. This research provides information to the widest possible audience at no charge to the reader because the subject company has funded the research.

It is important to differentiate between objective fee-based research and research that is promotional. Objective fee-based research is analogous to the role of your physician. You pay a physician not to tell you that you feel good, but to give you his or her professional and truthful opinion of your condition.

Legitimate fee-based research is a professional and objective analysis and opinion of a company's investment potential. Promotional research is short on analysis and full of hype. One example of this is the fax and email reports about the penny stocks that will supposedly triple in a short time.

Legitimate fee-based research firms have the following characteristics:

1. They provide analytical, not promotional services.
2. They are paid a set annual fee in cash; they do not accept any form of equity, which may cause conflicts of interest.
3. They provide full and clear disclosure of the relationship between the company and the research firm so investors can evaluate objectivity.

Companies who engage a legitimate fee-based research firm to analyze their stock are trying to get information to investors and improve market efficiency. Such a company is making the following important statements:

1. That it believes its shares are undervalued because investors are not aware of the company.
2. That it is aware that Wall Street is no longer an option.
3. That it believes that its investment potential can withstand objective analysis.

The National Investor Relations Institute (NIRI) was probably the first group to recognize the need for fee-based research. In January 2002, NIRI issued a letter emphasizing the need for small-cap companies to find alternatives to Wall Street research in order to get their information to investors. More recently, the NIRI is conducting a survey on research alternatives and will possibly have a session on this topic at their national conference this year. (For more information on fee-based research read Fee-Based Research: The Good, The Bad And The Ugly.)

The Bottom Line
The reputation and credibility of a company and the research firm depends on the efforts they make to inform investors. A company does not want to be tarnished by being associated with disreputable research. Similarly, a research firm will only want to analyze companies that have strong fundamentals and long-term investment potential.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

First-Time Clermont Homebuyers Face Unexpected Hurdles

Updated Category News Views 52

Welcome to the Wild Ride of Buying a Home! When folks step into the homebuying ring, especially in places like Clermont, Florida, they often don't realize how chaotic things can get. It's like being thrown into a boxing match without gloves. Brandie Mathison-Klein from the Mathison-Klein Group shines a light on this in a HelloNation piece, spilling the beans on what...

Continue Reading
Hybrid Bonding Market Shooting to $2.45 Billion by 2033

Updated Category News Views 68

Hybrid Bonding: The Future of Semiconductor Interconnects? Mark these words: Hybrid bonding isn't just another tech trend—it’s morphing into a billion-dollar juggernaut, my friend. With the latest numbers from MarketsandMarkets™, we see a potential leap from USD 0.38 billion in 2026 to a staggering USD 2.45 billion by 2033. We'll be seeing an eye-popping CAGR of...

Continue Reading
Pine AI Unveils AI Studio & Real-World Call Feature

Updated Category News Views 37

Push Your Expectations: Pine AI Takes the Stage Here's a twist in tech worth a double take. Pine AI is shaking up the AI world with a brash blend of video genius and actual chat capabilities. Somehow, merely weeks after setting the tech scene ablaze with its AI-focused computer, it's already rolling out new applications faster than hotcakes on a skillet. But let’s chew...

Continue Reading
Sasol Names Stanley Subramoney as Audit Chair

Updated Category News Views 183

Shifting Sands at Sasol's Audit Helm Ah, the boardroom dance continues. Sasol has just announced, loud and clear from Johannesburg, that Mr. Stanley Subramoney is stepping up as the new Chairman of their Audit Committee. This is no small shuffle in the deck. When it comes to keeping the books in check at big players like Sasol, you need a top-tier audit leader. Ain't no...

Continue Reading
Timken Maintains Robust Dividend Streak in 2026

Updated Category News Views 76

Timken Keeps Dividend Train Rolling You want to talk consistency? Timken Company just declared its quarterly dividend like clockwork. As a stockholder, that might just be your morning coffee fix before anything else. Notably, Timken's been on the NYSE since 1922, having cranked out 418 consecutive dividend payouts. That's like your grandpa never missing a Sunday golf...

Continue Reading
IM Cannabis's Third Quarter Financial Jolt

Updated Category News Views 91

IM Cannabis Takes a Hit, But Seeks New Angles Diving into IM Cannabis's (NASDAQ: IMCC) latest financial splash is like reading a weathered old map of the stock market. The third quarter of 2026 wasn't kind to this little cannabis outfit. Revenues have nosedived to C$1.65 million from last year's C$5.08 million. It's not just the typical bad quarter blues; it's a solid...

Continue Reading
TIGR Investors Eye Class Action Amid Legal Woes

Updated Category News Views 69

A Legal Storm Brews Over UP Fintech When it rains, it pours, and for UP Fintech Holding Limited, the sky's looking pretty stormy. Investors who jumped on the NASDAQ:TIGR bandwagon between April 2024 and June 2026 are finding themselves at the center of a nasty legal maelstrom. The allegations? Well, they're explosive, hinting at a pattern of unlicensed cross-border...

Continue Reading
CVRx Faces Legal Storm: Investors Grapple with Fallout

Updated Category News Views 45

CVRx in the Crosshairs: Legal and Operational Woes There's a storm brewing over at CVRx, Inc. (NASDAQ: CVRX), and it's pulling investors down a hell of a financial rabbit hole. You might think you're in the clear with a company like CVRx that boasts approved devices, but think again. Recent revelations have shown that even those with FDA stamps aren't immune to the...

Continue Reading
Finding the Right Auto Insurance: What to Consider

Updated Category News Views 79

Understanding the Basics of Auto Insurance Coverage Now, you might think the state knows best when it sets those minimum auto insurance requirements. But let's not kid ourselves—skimping on coverage can leave you high and dry if things go south on the road. That's where an expert voice like Corey Frazer's comes in, laying out why those limits often fall short. Minimum...

Continue Reading
Class Action Looms Over The Chemours Company

Updated Category News Views 126

Chemours Under Fire: What’s Happening? Here we are, in the thick of a legal storm surrounding The Chemours Company. A class-action lawsuit is underway, and it’s painting the company in a rather unflattering light. Now, if you snagged some of that NYSE:CC action between February 20, 2026, and August 4, 2026, there's a chance you’re caught in the crossfire. Per the...

Continue Reading

Top 5 Most Recently Viewed Articles

Cango Inc. Reports Impressive Bitcoin Production Growth

Updated Category News Views 107

Cango Inc. Performs Exceptionally in Bitcoin Mining Operations Cango Inc. has seen remarkable progress in its Bitcoin mining endeavors, as showcased by its recent production report. The company operates using a well-structured strategy, which has proven successful in driving growth within the cryptocurrency market. Key Metrics to Note The September report illustrates the...

Continue Reading
BWXT Awarded Deconversion Contract by U.S. DOE for HALEU

Updated Category News Views 162

BWXT's Achievement in Nuclear Fuel Deconversion Rich in innovation and commitment to nuclear solutions, BWX Technologies, Inc. (NYSE: BWXT) has recently announced a significant achievement. Their Nuclear Fuel Services, Inc. (NFS) division has been selected by the U.S. Department of Energy (DOE) as part of a prominent initiative. This recognition places BWXT at the...

Continue Reading
SEALSQ Showcases Quantum-Resistant Solutions at Quantum Days

Updated Category News Views 299

SEALSQ Showcases Quantum-Resistant Solutions at Quantum Days During a recent event, SEALSQ Corp (NASDAQ: LAES), a leader in semiconductor and post-quantum technology, demonstrated its commitment to cutting-edge security solutions. The event showcased live demonstrations highlighting the effectiveness of post-quantum cryptography (PQC) through their implementation of two...

Continue Reading
Ultragenyx Pharmaceutical Grants Stock Units to New Officers

Updated Category News Views 152

Ultragenyx Pharmaceutical Welcomes New Team Members Novato, California - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a dedicated biopharmaceutical entity, proudly reports the issuance of 20,820 restricted stock units to 13 newly hired non-executive officers as part of their employment inducement initiative. This decision, approved by the company's compensation...

Continue Reading
Alto Neuroscience Faces Class Action Amid Allegations of Fraud

Updated Category News Views 134

Alto Neuroscience Faces Class Action Lawsuit for Securities Issues In recent developments, Alto Neuroscience, Inc. finds itself at the center of a class action lawsuit alleging securities fraud, with significant implications for its investors. The lawsuit, spearheaded by prominent legal firm Levi & Korsinsky, LLP, aims to secure compensation for stockholders negatively...

Continue Reading